Dr. Thomas Mürdter | Institut für klinische Pharmakologie IKP

Major Projects

Influence of pharmacogenetics on the metabolism of Selective Estrogen Receptor Modulators
Synthesis and analysis of phase I and II metabolites
Ex vivo models of human tumors

Selected References

Kröner P, Heinkele G, Kerb R, Igel S, Schwab M, Mürdter TE. Stereoselective quantification of phase 1 and 2 metabolites of clomiphene in human plasma and urine. Talanta. 2021 Jan 1;221:121658

Neef SK, Janssen N, Winter S, Wallisch SK, Hofmann U, Dahlke MH, Schwab M, Mürdter TE, Haag M. Metabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS. Metabolites. 2020 Dec 1;10(12):494

Maximov PY, McDaniel RE, Fernandes DJ, Korostyshevskiy VR, Bhatta P, Mürdter TE, Flockhart DA, Jordan VC. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. Br J Pharmacol. 2014 Dec;171(24):5624-35

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2013 Jan 10;31(2):176-80

Dong M, Philippi C, Loretz B, Nafee N, Schaefer UF, Friedel G, Ammon-Treiber S, Griese EU, Lehr CM, Klotz U, Mürdter TE. Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2'-O-methyl-RNA. Int J Pharm. 2011 Oct 31;419(1-2):33-42

Major Networks and Collaborations

TAMENDOX: Genotype and phenotype guided supplementation of TAMoxifen standard therapy with ENDOXifen in breast cancer patients

Extramural Funding

BMBF (Federal Ministry of Education and Research): Initiative Individualized Medicine: TAMENDOX
DFG (German Research Foundation): The role of agonistic metabolites in Tamoxifen resistance

Curriculum Vitae

Education and Professional Career

Since 1997

Scientist at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology

1997

PhD in Chemistry. Thesis: Distribution, tumour selectivity, and bio-activation of doxorubicin in the isolated perfused human lung model.

1994-1997

PhD studies at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology

1992-1994

Deputy head of the Department of Polymer and Environmental Analysis at the Institute of Polymeric Sciences, Stuttgart, Germany

1991-1992

Research fellow at the Fraunhofer Institute for Interfacial Engineering and Biotechnology

1991

Diploma Thesis at the Department of Chemical Microbiology at the Fraunhofer Institute for Interfacial Engineering and Biotechnology: Degradation of trichloroethylene by the alcaligenes denitrificans ssp xylosoxidans strain JE95

1988-1991

Graduate studies in Chemistry with elective subject Biochemistry at University of Stuttgart

1988

Industrial traineeship at PLIVA Ltd. Zagreb, Yugoslavia

1984-1987

Undergraduate studies in Chemistry at University of Stuttgart

Professional Memberships

Since 1998: Member of the DGTP (German Society of Toxicology and Pharmacology)

Research Group

Tumor Models & Microenvironment

> Core Facility
Chemical Analytics & Synthesis

> Core Facility
Pharmacological Warehouse